A federal appeals court last week upheld a $2 million loss for C.R. Bard (NYSE:BCR) in a product liability lawsuit brought over its Avaulta pelvic mesh. A jury awarded plaintiff Donna Cisson $250,000 in compensatory damages and $1.75 million in punitive damages back in August 2013, in 1 of the 1st of thousands of federal lawsuits […]
C.R. Bard
AngioDynamics must face Bard patent infringement lawsuit
AngioDynamics (NSDQ:ANGO) must face a patent infringement lawsuit brought by Bard and subsidiary Bard Peripheral Vascular, a federal judge in Delaware ruled this week. Murray Hill, N.J.-based Bard sued AngioDynamics in March 2015, alleging that its Smart Port and other implantable power-injectable port products trespass on a trio of Bard patents, according to court documents. AngioDynamics asked […]
Jury adds $7 million in punitive damages to Johnson & Johnson’s $5.5m mesh loss
Johnson & Johnson (NYSE:JNJ) must pay $7 million in punitive damages on top of $5.5 million in compensatory damages it was ordered to pay yesterday in the 1st of a series of pelvic mesh lawsuits. Jurors took 2 hours of deliberation before they reached the $7 million figure, according to Law360.com. Johnson & Johnson and its Ethicon […]
Johnson & Johnson lose 1st Philly mesh case
A jury in Philadelphia ruled today that Johnson & Johnson (NYSE:JNJ) must pay $5.5 million in the 1st in a series of pelvic mesh lawsuits. The jury found J&J liable, based on the negligence of its scientists in relation to its Prolift pelvic mesh implant, citing it as the root cause of plaintiff Patricia Hammons’ […]
Gore wins round in stent graft bout with Bard
W.L. Gore & Associates won a round against C.R. Bard (NYSE:BCR) in an ongoing stent graft patent validity battle as a Delaware federal judge upheld the validity of 2 Gore stent graft patents. The court ruled that Gore’s patent on stent graft devices in tubes less than 0.1 millimeter was valid, rejecting Bard’s invalidity argument, […]
Bard, Boston Scientific in 1st trial against 2 pelvic mesh makers
A trial is under way in Kansas City in a product liability lawsuit against Boston Scientific (NYSE:BSX) and C.R. Bard (NYSE:BCR), marking the 1st time a pelvic mesh lawsuit against 2 companies has gone before a jury, Courtroom View Network reported. Plaintiff Eve Sherrer alleges that Bard’s Align and Boston Scientific’s Solyx used a polypropylene mesh that reacts to tissue by becoming brittle […]
Bard to pay $181m for DTC distributor Liberator Medical
C.R. Bard (NYSE:BCR) said today that it agreed to pay $181 million to acquire Liberator Medical (NYSE:LBMH), a direct-to-consumer distributor of durable medical equipment. The deal, expected to close during the 1st quarter next year, calls for Murray Hill, N.J.-based Bard to pay $3.35 per share for Liberator. The bid is a 36% premium over Liberator’s […]
VIVA 2015 Roundup: Medtronic touts Valiant stent graft, PAD stent-treatment data
Medtronic (NYSE:MDT) this week presented data from 2 studies of its stent systems and announced a new study of its In.Pact Admiral drug-coated balloon. The announcements were made at the VIVA physicians annual conference in Las Vegas, Nev. The Fridley, Minn.-based medical giant presented data from a 2-year clinical trial of its Valiant Captivia thoracic stent graft […]
Bard raises outlook after strong Q3 tops forecasts
C.R. Bard (NYSE:BCR) beat expectations with its 3rd-quarter results and raised its earnings outlook for the rest of 2015 yesterday, despite a swing to red ink. Murray Hill, N.J.-based Bard posted losses of -$86 million, or -$1.16 per share, on sales of $865.7 million for the 3 months ended Sept. 30. Although sales grew 4.3% compared […]
Baxter adds Boston Scientific CEO Mahoney to board | Personnel Moves
Baxter (NYSE:BAX) said today that it named Boston Scientific (NYSE:BSX) CEO Mike Mahoney to its board of directors. Mahoney, who engineered a significant turnaround at Boston Scientific, was tapped to serve on Baxter’s governance and compensation committees. “Mike’s significant knowledge of the global medical products business and his track record of leadership will make a significant contribution […]
TCT 2015: More 2-year data on Bard’s Lutonix DEB
C.R. Bard (NYSE:BCR) yesterday released 2-year results from a small group of patients in a real-world registry study of its Lutonix drug-eluting balloon at the annual Transcatheter Cardiovascular Therapeutics conference in San Franscisco. Bard said the Lutonix 035 device, which is designed to treat peripheral artery disease, showed a 94.3% rate of freedom from target lesion revascularization in […]